Impact of HPyV9 and TSPyV coinfection on the development of BK polyomavirus viremia and associated nephropathy after kidney transplantation

• Published in: Journal of medical virology 2019-06, Vol.91 (6), p.1142-1147
• Main Authors: van Rijn, Aline L., Wunderink, Herman F., de Brouwer, Caroline S., van der Meijden, Els, Rotmans, Joris I., Feltkamp, Mariet C. W.
• Format: Article
• Language: English
• Subjects: Adult; Aged; BK infection; BK polyomavirus; BK Virus - isolation & purification; BKPyV‐associated nephropathy; Cohort Studies; Coinfection - virology; Female; human polyomavirus 9; Humans; Infections; Kidney - virology; Kidney Diseases - virology; Kidney transplantation; Kidney Transplantation - adverse effects; Kidney transplants; Kidneys; Male; Middle Aged; Nephropathy; Patients; Polyomaviridae - isolation & purification; Polyomavirus Infections - etiology; Polyomavirus Infections - urine; Tissue Donors; Transplantation; trichodysplasia spinulosa polyomavirus; Tumor Virus Infections - etiology; Urinary tract; Urine; Viremia; Viremia - virology; Virology
• ISSN: 0146-6615; 1096-9071
• DOI: 10.1002/jmv.25397

Background BK polyomavirus (BKPyV) persistently infects the urinary tract and causes viremia and nephropathy in kidney transplantation (KTx), recipients. In a previous study, we observed an increased incidence and load of BKPyV viremia in KTx patients coinfected with human polyomavirus 9 (HPyV9). Here we sought confirmation of this observation and explored whether novel HPyVs that have been detected in urine (HPyV9 and trichodysplasia spinulosa polyomavirus [TSPyV]) potentially aggravate BKPyV infection. Methods A well‐characterized cohort of 209 KTx donor‐recipient pairs was serologically and molecularly analyzed for HPyV9 and TSPyV coinfection. These data were correlated with the occurrence of BKPyV viremia and BKPyVAN in the recipients within a year after KTx. Results Seropositivity for HPyV9 (19%) and TSPyV (89%) was comparable between donors and recipients and did not correlate with BKPyV viremia and BKPyVAN that developed in 25% and 3% of the recipients, respectively. Two recipients developed TSPyV viremia and none HPyV9 viremia. Modification of the predictive effect of donor BKPyV seroreactivity on recipient BKPyV viremia by HPyV9 and TSPyV was not observed. Conclusions Our data provide no evidence for a promoting effect of HPyV9 and TSPyV on BKPyV infection and BKPyVAN in renal allograft patients. Therefore, we do not recommend including HPyV9 and TSPyV screening in KTx patients.